Denali Therapeutics News

Positive Outlook for Denali Therapeutics: Accelerated Approval and Financial Strategy Strengthening Market Position

TipRanks09:25 ET

Express News | Flagship Pioneering- $600 Mln in Payments From Novo Nordisk, to Be Shared Between Metaphore, Pioneering Medicines

Reuters07:11 ET

Express News | Flagship Pioneering-Upto $600 Mln in Upfront, Development,Commercial Milestone Payments, Tiered Royalties on Annual Net Sales of Products From Novo

Reuters07:10 ET

Express News | Flagship Pioneering Flagship Pioneering and Metaphore Biotechnologies Announce Research Collaboration With Novo Nordisk to Develop Next-Generation Therapeutics for Obesity Management

Reuters07:03 ET

Denali Therapeutics First Quarter 2024 Earnings: US$0.68 Loss per Share (Vs US$0.80 Loss in 1Q 2023)

Yahoo Finance06:19 ET

Express News | Denali Therapeutics Inc : Oppenheimer Cuts Target Price to $50 From $60

Reuters01:14 ET

Denali Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.

Denali Therapeutics Shares Are Trading Higher After the Company Reported Q1 Financial Results.

Benzinga13:04 ET

Stifel Adjusts Price Target on Denali Therapeutics to $22 From $26, Maintains Hold Rating

Denali Therapeutics (DNLI) has an average buy rating and a price target range of $22 to $95, according to analysts polled by Capital IQ. Price: 19.30, Change: +2.45, Percent Change: +14.51

MT NewswiresMay 8 11:17 ET

Louisiana-Pacific Posts Upbeat Results, Joins Cricut, Elanco Animal, American Public Education And Other Big Stocks Moving Higher On Wednesday

U.S. stocks were mixed, with the Dow Jones gaining around 70 points on Wednesday.Shares of Louisiana-Pacific Corporation (NYSE:LPX) rose sharply during Wednesday's session following better-than-expec

BenzingaMay 8 11:11 ET

Denali Therapeutics Is Maintained at Outperform by Wedbush

Denali Therapeutics Is Maintained at Outperform by Wedbush

Dow JonesMay 8 10:30 ET

Denali Therapeutics Price Target Cut to $30.00/Share From $31.00 by Wedbush

Denali Therapeutics Price Target Cut to $30.00/Share From $31.00 by Wedbush

Dow JonesMay 8 10:30 ET

Wedbush Maintains Outperform on Denali Therapeutics, Lowers Price Target to $30

Wedbush analyst Laura Chico maintains Denali Therapeutics with a Outperform and lowers the price target from $31 to $30.

Analyst UpgradesMay 8 10:20 ET

Denali Therapeutics Is Maintained at Hold by Stifel

Denali Therapeutics Is Maintained at Hold by Stifel

Dow JonesMay 8 09:37 ET

Denali Therapeutics Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Denali Therapeutics Price Target Maintained With a $95.00/Share by HC Wainwright & Co.

Dow JonesMay 8 09:37 ET

Denali Therapeutics Price Target Cut to $22.00/Share From $26.00 by Stifel

Denali Therapeutics Price Target Cut to $22.00/Share From $26.00 by Stifel

Dow JonesMay 8 09:37 ET

Stifel Maintains Hold on Denali Therapeutics, Lowers Price Target to $22

Stifel analyst Paul Mattels maintains Denali Therapeutics with a Hold and lowers the price target from $26 to $22.

Analyst UpgradesMay 8 09:19 ET

Wedbush Adjusts Denali Therapeutics' Price Target to $30 From $31, Keeps Outperform Rating

Denali Therapeutics (DNLI) has an average rating of buy and price targets ranging from $22 to $95, according to analysts polled by Capital IQ.

MT NewswiresMay 8 09:16 ET

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $95 Price Target

HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $95 price target.

BenzingaMay 8 09:11 ET

Denali (DNLI) Q1 Earnings Miss, Pipeline Progress in Focus

Yahoo FinanceMay 8 08:20 ET

Express News | Denali Therapeutics Inc : Wedbush Cuts Target Price to $30 From $31

ReutersMay 8 08:02 ET